中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 11
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(11): 2520-2525

Construction and validation of a nomogram model for microvascular invasion in hepatocellular carcinoma based on the characteristics on contrast-enhanced ultrasound Liver Imaging Reporting and Data System

DOI: 10.3969/j.issn.1001-5256.2022.11.016
  • 1.

    Department of Ultrasound, Wujin Hospital Affiliated to Jiangsu University, Wujin Clinical College, Xuzhou Medical University, Changzhou, Jiangsu 213000, China

  • 2.

    Department of Ultrasound, Changzhou Third People's Hospital, Changzhou, Jiangsu 213000, China

Research funding:

2019 General Medical Research Project of Jiangsu Provincial Health Commission (H201982)

More Information
  • Corresponding author: GU Meiqin, gu8210mq@126.com(ORCID: 0000-0002-8938-5343)
  • Received Date: 2022-04-12
  • Accepted Date: 2022-06-15
  • Published Date: 2022-11-20
    Abstract
  •   Objective  To construct and validate a nomogram model for predicting microvascular invasion (MVI) based on the characteristics on contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS) in patients with hepatocellular carcinoma (HCC).  Methods  A total of 262 patients with HCC who were diagnosed in Wujin Hospital Affiliated to Jiangsu University from January 2017 to July 2020 were enrolled and randomly divided into modeling group and validation group at a ratio of 1∶ 1, with 131 patients in each group. MVI was confirmed by postoperative microscopic pathological results, and there were 70 patients with MVI in the modeling group and 56 patients with MVI in the validation group. CEUS was used to evaluate LI-RADS characteristics for the two groups. The independent samples t-test was used for comparison of continuous data between the two groups, and the chi-square test was used for comparison of categorical data between the two groups. Univariate and multivariate Logistic regression analyses were used to identify the risk factors for MVI in the modeling group; the receiver operating characteristic (ROC) curve was plotted, and the area under the ROC curve (AUC) was calculated for the model in predicting MVI to evaluate the accuracy of prediction; a decision curve analysis was used to evaluate the consistency of the model, and dispersion was compared between the calibration curve and the standard curve for the model in predicting MVI.  Results  There were no significant differences in clinical data and CEUS findings between the modeling group and the validation group (all P > 0.05). The univariate analysis showed that compared with the MVI-negative patients, the MVI-positive patients had significant increases in serum alpha fetoprotein (AFP) level, tumor diameter, and LR-5 "late and mild washout" and LR-M "early washout" on LI-RADS, as well as a significantly higher LI-RADS grade (all P < 0.05). The multivariate analysis showed that AFP 20-400 ng/mL (odds ratio [OR]=2.65, P < 0.001), AFP≥400 ng/mL (OR=3.98, P < 0.001), tumor diameter ≥30 mm (OR=2.12, P < 0.001), and LR-M on CEUS (OR=3.24, P < 0.001) were independent risk factors for MVI. The ROC curve analysis showed that the nomogram had an AUC of 0.867 and 0.821 in predicting MVI in the modeling group and the validation group, respectively. The nomogram model had a C-Index of 0.765 (95% confidence interval: 0.701-0.834). The calibration curves of the nomogram model were close to the standard curve in both groups.  Conclusion  The nomogram model based on LI-RADS obtained by CEUS in combination with AFP and tumor diameter has a good application value and can guide the preoperative screening for patients at a high risk of MVI and the development of appropriate surgical plans in clinical practice.

     

    • FullText(HTML)
  • loading
    • References(22)
  • [1]
    HE YZ, HE K, HUANG RQ, et al. Preoperative evaluation and prediction of clinical scores for hepatocellular carcinoma microvascular invasion: a single-center retrospective analysis[J]. Ann Hepatol, 2020, 19(6): 654-661. DOI: 10.1016/j.aohep.2020.07.002.
    [2]
    LIU ZY, WU D, OU JL, et al. Characteristics and related clinical indicators of microvascular invasion in hepatocellular carcinoma[J] J Hepatopancreatobiliary Surg, 2017, 29(2): 107-111. DOI: 10.11952/j.issn.1007-1954.2017.02.005.

    刘臻玉, 武丹, 区锦玲, 等. 肝癌微血管侵犯的特点及相关临床指标[J]. 肝胆胰外科杂志, 2017, 29(2): 107-111. DOI: 10.11952/j.issn.1007-1954.2017.02.005.
    [3]
    ERSTAD DJ, TANABE KK. Prognostic and therapeutic implications of microvascular invasion in hepatocellular carcinoma[J]. Ann Surg Oncol, 2019, 26(5): 1474-1493. DOI: 10.1245/s10434-019-07227-9.
    [4]
    ZENG YM, LIU D, TANG CL, et al. Clinical value of contrast-enhanced ultrasound and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the diagnosis of hepatocellular carcinoma[J]. Chin J Dig Surg, 2020, 19(10): 1098-1107. DOI: 10.3760/cma.j.cn115610-20200921-00628.

    曾杨媚, 刘灯, 唐春霖, 等. 超声造影与钆塞酸二钠增强磁共振检查诊断肝细胞癌的临床价值[J]. 中华消化外科杂志, 2020, 19(10): 1098-1107. DOI: 10.3760/cma.j.cn115610-20200921-00628.
    [5]
    LI R, FAN HJ, XU J, et al. The predictive value of contrast-enhanced ultrasound, serum AFP and CEA levels on microvascular invasion and early recurrence of liver cancer after interventional surgery[J]. Pract J Cancer, 2021, 36 (3): 452-456. DOI: 10.3969/j.issn.1001-5930.2021.03.027.

    李冉, 范会军, 徐杰, 等. 超声造影、血清AFP、CEA水平对肝癌介入术后微血管侵犯、早期复发的预测价值[J]. 实用癌症杂志, 2021, 36(3): 452-456. DOI: 10.3969/j.issn.1001-5930.2021.03.027.
    [6]
    DIETRICH CF, NOLSØE CP, BARR RG, et al. Guidelines and good clinical practice recommendations for Contrast-Enhanced Ultrasound (CEUS) in the liver-update 2020 WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS[J]. Ultrasound Med Biol, 2020, 46(10): 2579-2604. DOI: 10.1016/j.ultrasmedbio.2020.04.030.
    [7]
    WU QY, LIU J, YANG CS, et al. Application value of imaging examinations in the diagnosis of small hepatocellular carcinoma[J]. Chin J Dig Surg, 2022, 21(4): 543-550. DOI: 10.3760/cma.j.cn115610-20220321-00146.

    伍秋艳, 刘娟, 杨崇双, 等. 影像学检查在诊断小肝癌中的应用价值[J]. 中华消化外科杂志, 2022, 21(4): 543-550. DOI: 10.3760/cma.j.cn115610-20220321-00146.
    [8]
    WU JY, BAI XM, WANG H, et al. The perfusion features of recurrent hepatocellular carcinoma after radiofrequency ablation using contrast-enhanced ultrasound and pathological stemness evaluation: compared to initial tumors[J]. Front Oncol, 2020, 10: 1464. DOI: 10.3389/fonc.2020.01464.
    [9]
    DONG Y, QIU Y, YANG D, et al. Potential application of dynamic contrast enhanced ultrasound in predicting microvascular invasion of hepatocellular carcinoma[J]. Clin Hemorheol Microcirc, 2021, 77(4): 461-469. DOI: 10.3233/CH-201085.
    [10]
    FAN PL, DING H, MAO F, et al. Enhancement patterns of small hepatocellular carcinoma (≤ 30 mm) on contrast-enhanced ultrasound: Correlation with clinicopathologic characteristics[J]. Eur J Radiol, 2020, 132: 109341. DOI: 10.1016/j.ejrad.2020.109341.
    [11]
    KIM YY, KIM MJ, KIM EH, et al. Hepatocellular carcinoma versus other hepatic malignancy in cirrhosis: Performance of LI-RADS version 2018[J]. Radiology, 2019, 291(1): 72-80. DOI: 10.1148/radiol.2019181995.
    [12]
    LEI Z, LI J, WU D, et al. Nomogram for preoperative estimation of microvascular invasion risk in hepatitis B virus-related hepatocellular carcinoma within the Milan criteria[J]. JAMA Surg, 2016, 151(4): 356-363. DOI: 10.1001/jamasurg.2015.4257.
    [13]
    GRANATA V, FUSCO R, SETOLA SV, et al. Microvascular invasion and grading in hepatocellular carcinoma: correlation with major and ancillary features according to LIRADS[J]. Abdom Radiol (NY), 2019, 44(8): 2788-2800. DOI: 10.1007/s00261-019-02056-6.
    [14]
    SUN Z, SHAO WW, SONG JH. Progress in diagnosis and treatment of hepatocellular carcinoma with microvascular invasion[J/CD]. Chin J Hepat Surg(Electronic Edition), 2021, 10(3): 235-241.

    孙振, 邵巍伟, 宋京海. 肝细胞癌合并微血管侵犯的诊疗进展[J/CD]. 中华肝脏外科手术学电子杂志, 2021, 10(3): 235-241.
    [15]
    LIU LF, LIU JJ, LUO T, et al. Value of preoperative ultrasound combined with serum alpha fetoprotein in predicting microvascular invasion of hepatocellular carcinoma[J]. J Guangxi Med Univ, 2018, 35(9): 1260-1263. DOI: 10.16190/j.cnki.45-1211/r.2018.09.019.

    刘连凤, 刘军杰, 罗涛, 等. 术前超声联合血清甲胎蛋白水平预测肝癌微血管侵犯的价值[J]. 广西医科大学学报, 2018, 35(9): 1260-1263. DOI: 10.16190/j.cnki.45-1211/r.2018.09.019.
    [16]
    JIN Y, LI JT. Research progress on clinical related factors and molecular markers of microvascular invasion by liver cancer cells[J]. J Clin Hepatol, 2013, 29(7): 550-553. DOI: 10.3969/j.issn.1001-5256.2013.07.020.

    金赟, 李江涛. 肝癌细胞侵犯微血管的临床相关因素及分子标志物的研究进展[J]. 临床肝胆病杂志, 2013, 29(7): 550-553. DOI: 10.3969/j.issn.1001-5256.2013.07.020.
    [17]
    KIM SS, LEE S, KIM MJ. Prognostic factors of gadoxetic acid-enhanced MRI for postsurgical outcomes in multicentric hepatocellular carcinoma[J]. Eur Radiol, 2021, 31(5): 3405-3416. DOI: 10.1007/s00330-020-07419-y.
    [18]
    KONO Y, LYSHCHIK A, COSGROVE D, et al. Contrast Enhanced Ultrasound (CEUS) Liver Imaging Reporting and Data System (LI-RADS®): the official version by the American College of Radiology (ACR)[J]. Ultraschall Med, 2017, 38(1): 85-86. DOI: 10.1055/s-0042-124369.
    [19]
    ZHOU H, ZHANG C, DU L, et al. Contrast-enhanced ultrasound liver imaging reporting and data system in diagnosing hepatocellular carcinoma: Diagnostic performance and interobserver agreement[J]. Ultraschall Med, 2022, 43(1): 64-71. DOI: 10.1055/a-1168-6321.
    [20]
    ZHU W, QING X, YAN F, et al. Can the contrast-enhanced ultrasound washout rate be used to predict microvascular invasion in hepatocellular carcinoma?[J]. Ultrasound Med Biol, 2017, 43(8): 1571-1580. DOI: 10.1016/j.ultrasmedbio.2017.04.003.
    [21]
    CARR BI, INCE V, BAG HG, et al. Microscopic vascular invasion by hepatocellular carcinoma in liver transplant patients[J]. Clin Pract (Lond), 2020, 17(3): 1497-1505.
    [22]
    WANG P, NIE F, DONG T, et al. Study on correlation between two-dimensional ultrasound, contrast-enhanced ultrasound and microvascular invasion in hepatocellular carcinoma[J]. Clin Hemorheol Microcirc, 2022, 80(2): 97-106. DOI: 10.3233/CH-211190.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (254) PDF downloads(30) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return